Authors
Latest:
Silver Linings of a Global Health Crisis: A New Path Forward for Pharma Media Professionalsat some point, we won’t be seeing wall-to-wall COVID coverage anymore, but stories about the fallout. How can pharmaceutical brands prepare for what’s next?
Latest:
Industry Predictions For 2023Top industry experts weigh in on what the new year holds for the pharma industry.
Latest:
Instead of Drug Spending Caps, Medicare Should Try Value-Based ContractingNew regulations may require regulators to explore new payment options.
Latest:
Precision & Specialty Medicine Clinical TrialsPrecision & Specialty Medicines are driving changes in the pharma development industry. We explore the changes these paradigms are having on the clinical trial space.
Latest:
Shining a Light on Rare Disease: Evidence Challenges and SolutionsSignificant challenges still lie ahead, but several specialists and a plethora of new technologies are well positioned to gather and analyze the evidence needed for diagnosing and treating rare diseases, writes Catherine Tak Piech.
Latest:
Competing in Commercial Pharmaceuticals: Get Formal and Familiar with AnalyticsExploring the importance of analytics as a means of staying competitive in the commercial pharmaceutical market.
Latest:
Is Model Informed Drug Development Regulatory Pathway an Exception or the Norm?MIDD can pave new road for drug development.
Latest:
The Leap Forward: Practical Gains for Pharma AI UseExploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.
Latest:
Four Critical Considerations for Launching Digital Diagnostic ToolsCreating a digital diagnostic that is supplemental and strategic to a company’s therapeutic asset requires due diligence to monetize the digital health innovation, or at least ensure optionality through the product development cycle.
Latest:
Open Science and Digital Health: A Brighter Future for Parkinson’s DiseaseCollaborative efforts among researchers, clinicians, and industry are essential to unlock the full potential of digital health in transforming the lives of people with Parkinson's disease.
Latest:
What Makes for a Great Leader in Pharma, and How to Hire OneA look into the traits that hiring managers of pharma companies should be searching for when hiring for a leadership role.
Latest:
Virtual Medical Affairs Audits: A Viable AlternativeVirtual audits proving to be beneficial post-COVID despite continuing challenges.
Latest:
3 Steps to Supercharge Your Rare Disease Advocacy PartnershipsHow these actions can help brand teams form effective and sustainable relationships with patient communities
Latest:
Artificial Intelligence Makes Possible a Multiomic Approach in Oncology Drug DiscoveryWhile challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates more quickly and efficiently with applications in target discovery, structure prediction, and drug optimization.
Latest:
More Than a Trend: Steps to Ensure Patient-Centered Research Stays at the Forefront of PharmaPharma companies are now under increasing pressure, and increasingly willing, to offer a patient-centric approach. But with this increasing demand comes confusion about what patient-centered research actually is.
Latest:
The Architecture of Global, Scalable, Next-Generation Patient Support ProgramsPatient support programs (PSPs) have an opportunity for growth and innovation.
Latest:
Tapping NPs and PAs in Life Sciences MarketingAmid the shifting focus from primary care to specialty care, using data-driven tactics can create tailored campaigns and meaningful relationships with nurse practitioners and physician assistants.
Latest:
The Shifting Landscape of the Life Sciences Job MarketPlanning for a post-recession scenario is essential, ensuring companies are prepared to scale up when funding permits.
Latest:
Why Program Management is the Key to Success for Life Science CompaniesDelivering value with enterprise program management.
Latest:
From Clinical Trials to Market Success: 3 Approaches You Can Use Right Now for Allogeneic TherapiesPatient centricity and access highlight keys to success for new development.
Latest:
The Intelligent AI ConsumerArtificial Intelligence (AI) fueled by real-world healthcare data has yet to be fully leveraged by biopharmaceutical companies but is poised to revolutionize their business strategies.
Latest:
Ecolab Continues Mission to Protect What's Vital With Deep Investment in Life SciencesEcolab is looking to the future with new opportunities to partner with Pharma for critical solutions to support drug development and manufacturing.
Latest:
PREP Act Protections for COVID-19 Vaccine LiabilityHow PREP Act protections will apply to potential COVID-19 vaccine-related claims.
Latest:
Best Practices for Balancing Medical Affairs Globalization with Local RequirementsAddressing the challenges faced by Global Medical Affairs teams and how they can find balance to create maximum value for their organizations.
Latest:
The IRA Impact: Navigating Its Evolving ComplexitiesAmid lingering questions and uncertainty, a look at ways pharma companies can prioritize incorporating the Inflation Reduction Act into their strategic planning process—and do it now.
Latest:
Navigating Cross-Border Pharma Deals: Key Trends and Lessons Out of ChinaThe importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.
Latest:
The Quest to Fully Address Prescription Drug AffordabilityThe Medicare Part D cap won’t solve need for financial assistance.
